Evidence map›Paper›PMID 38796530›Full record

ArticleLeukemia2024

TP53 mutation screening for patients at risk of myeloid malignancy.

Devdeep Mukherjee, Rialnat A Lawal, Courtney D Fitzhugh, Christopher S Hourigan, Laura W Dillon

Abstract readLetter
PubMed Publisher
In one paragraph

Article in Leukemia, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

  • Update of
    2024
5 · Who and what money

Authors and funding

5 authors.

Devdeep Mukherjee *Laboratory of Myeloid Malignancies, Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA.
Rialnat A Lawal *Cellular and Molecular Therapeutics Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA.
Courtney D FitzhughCellular and Molecular Therapeutics Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA.ORCID 0000-0002-5306-7167
Christopher S HouriganLaboratory of Myeloid Malignancies, Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA. hourigan@vt.edu.ORCID 0000-0002-6189-8067
Laura W DillonLaboratory of Myeloid Malignancies, Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA.ORCID 0000-0002-4877-9354

Funding

Nonmyeloablative haploidentical peripheral blood stem cell transplantation in congenital anemiasZIAHL006211 · NHLBI · NATIONAL HEART, LUNG, AND BLOOD INSTITUTE · PI FITZHUGH, COURTNEY · 2016 to 2025
$19.4M
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

MutationTumor Suppressor Protein p53AdultAgedDNA Mutational AnalysisFemaleHumansMaleMiddle AgedMyeloproliferative DisordersTP53 protein, humanTumor Suppressor Protein p53

Identifiers

PMID38796530

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.